GLAUKOS CORP (GKOS)
Health Care · Ophthalmic Medical Devices & Pharmaceuticals · NYSE
A commercial-stage ophthalmic medical technology and pharmaceutical company focused on novel, dropless therapies for glaucoma, corneal disorders, and retinal diseases.
What GLAUKOS CORP does
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company that develops and commercializes innovative therapies for glaucoma, corneal disorders, and retinal diseases. Its portfolio includes Micro-Invasive Glaucoma Surgery (MIGS) medical devices and sustained-release pharmaceutical products. The company is transitioning its corneal cross-linking portfolio toward its newer, incision-free bio-activated therapy, Epioxa.
Themes: glaucoma treatment, corneal disorders / keratoconus, retinal disease therapeutics, minimally invasive surgery, sustained-release drug delivery
Fundamentals
- Price$161.29 as of 2026-10-08 close
- Market cap$9.5B as of 2026-07-28 (share count; price 2026-10-08)
- 1-year return+84.1% 2025-10-08 close $87.59 → 2026-10-08 close $161.29
- P/En/a negative earnings
- Net margin-37.0% FY2025, SEC XBRL
- Gross margin+55.7% FY2025, SEC XBRL
- ROE-28.6% FY2025, SEC XBRL
- Debt / equity0.10 as of 2026-09-03
- Revenue growth (YoY)+41.5% as of 2026-09-03
- Revenue CAGR (3y)+21.5% SEC XBRL
- Beta1.28 as of 2026-09-03
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
How GKOS compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
GKOS is not currently in any published Top 10 list. Its scores are below.
Top 10 score
Not scored for the top 10 list: it is in the most expensive tenth of the field on valuation, so it is ranked as a growth story rather than on fundamentals.
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How GLAUKOS CORP looks technically
GLAUKOS CORP (GKOS) is trading 18.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 199 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive). It made a new 20-day low about 12 trading days ago. It is 15.8% below its highest point of the past year. Trading volume is running unusually high — about 3.6× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 18.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +18.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $172.80 | $172.80 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $135.95 | $135.95 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 151.01. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 199 trading days ago — a "golden cross", a bullish long-term signal | 199 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend) | 19.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) | 45.5 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($146.38 to $174.48) — its "stochastic" reading is 53 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 53.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $191.55 | $191.55 |
|---|---|---|
| From the 52-week high | it is 15.8% below its 52-week high (its highest price of the past year) | -15.8% |
| Above the 52-week low | it is 120.5% above its 52-week low (its lowest price of the past year) | +120.5% |
| Below the 52-week high | it is 15.8% below its highest point of the past year | 15.8% |
| Since a 20-day breakout | it made a new 20-day low about 12 trading days ago | 12 sessions |
| Since a 55-day breakout | it made a new 55-day high about 36 trading days ago | 36 sessions |
| All-time high | its highest closing price on record is $191.55 (set on 2026-08-20) | $191.55 |
| Given back of the 52-week move | over the past year its closes ranged ($74.67 to $189.55), and it has given back roughly a quarter of its rise from last year’s low — 25% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $114.88 to $118.55. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 24.6% |
| From the all-time high | it is 15.8% below its all-time high | -15.8% |
| Nearest price level | it is sitting right on a resistance level at $162.04 — a price it turned at four times since 2025-01-10, most recently on 2026-07-16. Since 2024-10-08 it has 13 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.5% |
| All-time low | its lowest closing price on record is $14.25 (set on 2016-02-08) | $14.25 |
| Above the all-time low | it is 1031.9% above its all-time low | +1,032% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 89% of it) | 11th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $8.15 between its high and its low — about 5.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $8.15 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $152.20 and $172.82 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $152.20 – $162.51 – $172.82 |
| Typical daily range (% of price) | its price moves about 5.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.0% |
| Stretch from the 200-day average | it is trading 3.1 daily ranges above its 200-day average price (18.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 3.6× its 30-day average, a sign of heightened interest | 3.59× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.9% |
|---|---|---|
| Gap filled | a 2.7% gap up opened on 2026-10-02 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 13.9 percentage points (the stock lost 12.8% while the market gained 1.0%) | -13.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 1.6 percentage points (the stock gained 5.4% while the market gained 3.8%) | +1.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 20.8 percentage points (the stock gained 38.2% while the market gained 17.5%) | +20.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 69.2 percentage points (the stock gained 84.1% while the market gained 15.0%) | +69.2% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 10.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 17% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $137.82 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | +17.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is under water. That average is $170.25 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -5.3% |
Price levels it has turned at before
GKOS last closed at $161.29 on 2026-10-08. Since 2024-10-08 it has turned at 13 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $162.04 | Resistance | 0.5% above the last close | turned there four times · 2025-01-10 to 2026-07-16 |
| $152.51 | Support | 5.4% below the last close | turned there three times · 2024-12-26 to 2026-09-25 |
| $146.98 | Support | 8.9% below the last close | turned there 7 times · 2024-11-13 to 2026-07-29 |
| $142.61 | Support | 11.6% below the last close | turned there twice · 2025-01-15 to 2025-02-12 |
| $184.68 | Resistance | 14.5% above the last close | turned there twice · 2026-07-30 to 2026-09-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $151.01.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $196.78 and $225.07 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $151.01.
This reading has stood for 5 trading days, since 2026-10-02.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Unusually heavy trading volume · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · beating the market · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.36 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$198.69 range $172.00 – $225.00; median $200.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GKOS
- Consensus EPS estimate-$0.08984 next reporting period, as of 2026-10-09
- Estimate change, 30 days-$0.00077 from -$0.08907, on 2026-09-04, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of net losses and significant accumulated deficit.","Exposure to macroeconomic volatility, supply chain disruptions, and potential tariff-related cost increases.","Risks associated with the commercial transition from existing products to new pipeline therapies."]
What changed in the latest 10-Q
AI-assisted comparison of GKOS's 10-Q filed 2026-07-29 against the prior one filed 2026-04-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing reports net sales of $185,610 and $336,181 for the three and six months ended June 30, 2026, compared to $124,120 and $230,784 for the same periods in 2025.
- Newer filing reports gross margin of 82% and 80% for the three and six months ended June 30, 2026, compared to 78% for both periods in 2025.
- Newer filing reports operating expenses of $168,861 and $305,949 for the three and six months ended June 30, 2026, compared to $119,913 and $222,939 for the same periods in 2025.
- Newer filing reports cash, cash equivalents, short-term investments and restricted cash of $289,341 as of June 30, 2026.
- Newer filing reports net losses of $18.4 million and $38.2 million for the three and six months ended June 30, 2026, and net losses of $19.7 million and $37.8 million for the same periods in 2025.
- Newer filing reports an accumulated deficit of $971.3 million as of June 30, 2026.
- Newer filing states the Epioxa J-code became effective on July 1, 2026, whereas the older filing stated it was set to become effective on July 1, 2026.
- Newer filing states the transition from Photrexa to Epioxa is projected to be completed by the end of the third quarter of 2026, while the older filing stated it would occur over the course of 2026.
- Newer filing references 'the related blockage of the Straight of Hormuz' in connection with the U.S.-Iran conflict and its effects on oil prices.
- Removed:
- Older filing reports net sales of $150,571 for the three months ended March 31, 2026, compared to $106,664 for the same period in 2025.
- Older filing reports gross margin of 78% and 77% for the three months ended March 31, 2026 and March 31, 2025, respectively.
- Older filing reports operating expenses of $137,088 and $103,026 for the three months ended March 31, 2026 and March 31, 2025, respectively.
- Older filing reports cash, cash equivalents, short-term investments and restricted cash of $280,519 as of March 31, 2026.
- Older filing reports net losses of $19.8 million and $18.1 million for the three months ended March 31, 2026 and March 31, 2025, respectively.
- Older filing reports an accumulated deficit of $952.9 million as of March 31, 2026.
- Older filing describes the February 9, 2026 Option Agreement with a biopharmaceutical company, including upfront payments up to $17.5 million, future milestone payments, and acquisition election terms.
- Older filing states the transition from Photrexa to Epioxa would occur over the course of 2026.
- Older filing reports the international glaucoma franchise was positively affected by approximately 770 basis points for the three months ended March 31, 2026 and negatively impacted by approximately 380 basis points for the three months ended March 31, 2025, primarily related to the Euro.
- Reworded:
- Overview section: newer filing changed 'novel, dropless platform therapies' (with comma) to 'novel dropless platform therapies' (without comma).
- Financial Overview table: newer filing presents data for three and six months ended June 30, 2026 and 2025, replacing the older filing's data for three months ended March 31, 2026 and 2025.
- Newer filing adds six-month 2025 comparative figures for net sales, gross margin, and operating expenses that were not present in the older filing.
- Newer filing revises the foreign currency discussion to cover three and six months ended June 30, 2026 (approximately 85 and 420 basis points positive, primarily related to the Euro, Australian dollar and Brazilian Real, partially offset by the Japanese Yen) and three and six months ended June 30, 2025 (approximately 410 and 25 basis points positive, primarily related to the Euro and Japanese yen), replacing the older filing's discussion of three months ended March 31, 2026 and 2025.
- Newer filing changes 'changes in supply and demand' to 'volatility in in supply and demand conditions' (including a duplicated 'in in') and modifies the tariff discussion by removing 'including new or increased tariffs' from the list of uncertainty factors, instead incorporating tariff specifics in the following paragraph.
- Newer filing begins the Recent Developments section with the April 15, 2026 CMS J-code announcement, omitting the February 9, 2026 Option Agreement entry that appeared in the older filing.
- Newer filing changes the Epioxa transition description from 'over the course of 2026' to 'with completion of the transition projected to occur by the end of the third quarter of 2026'.
- Newer filing truncates the 'Developments Impacting Reimbursement Rates and Coverage' section mid-sentence at 'As of June 30, 2026, the profess', while the older filing does not include this section in the provided excerpts.
- Notes:
- The newer filing text is truncated at the end of the 'Developments Impacting Reimbursement Rates and Coverage' section, and the older filing text is also truncated at 'such as' in the same section; complete comparison of that section is not possible.
- The older filing excerpt does not include the full 'Developments Impacting Reimbursement Rates and Coverage' section, so changes in that section beyond the truncation point cannot be assessed.
- No interpretation of the materiality or significance of any reported change is provided.
Risk Factors
- Added:
- Newer filing (filed 2026-07-29) lists 'Epioxa' among products generating net sales (phrase changed from 'Photrexa and other associated drug formulations' to 'Photrexa, Epioxa and other associated drug formulations').
- Newer filing (filed 2026-07-29) includes three-month amortization expense of $5.8 million for each of the three months ended June 30, 2026 and June 30, 2025.
- Newer filing (filed 2026-07-29) includes six-month amortization expense of $14.9 million and $11.4 million for the six months ended June 30, 2026 and June 30, 2025, respectively.
- Newer filing (filed 2026-07-29) mentions 'litigation' in expected SG&A cost increases (phrase changed from 'general legal costs' to 'general legal and litigation costs').
- Removed:
- Older filing (filed 2026-04-30) included three-month amortization expense of $8.8 million and $5.6 million for the three months ended March 31, 2026 and March 31, 2025, respectively (not present in newer filing).
- Older filing (filed 2026-04-30) included 'Epioxa' in the list of products with relatively low production volumes ('iDose TR , Epioxa and our proprietary CXL bioactivation systems') whereas newer filing lists 'iDose TR and our proprietary CXL bioactivation systems' without Epioxa.
- Older filing (filed 2026-04-30) concluded the R&D section with the sentence 'We are not currently able to fully track expenses by product candidate.', which does not appear in the newer excerpt.
- Reworded:
- In Net Sales, newer filing (filed 2026-07-29) changed product listing from 'Photrexa and other associated drug formulations and our proprietary bioactivation systems' to 'Photrexa, Epioxa and other associated drug formulations, and our proprietary bioactivation systems'.
- In Cost of Sales, newer filing (filed 2026-07-29) changed amortization disclosure from the three months ended March 31, 2026/2025 at $8.8M/$5.6M (older filing, filed 2026-04-30) to the three months ended June 30, 2026/2025 at $5.8M each, and added six-month figures.
- Notes:
- The newer excerpt ends mid-sentence ('our likelihood of obtaining nece'), so the comparison may be incomplete for the remainder of the R&D section.
- The provided texts appear to be from the 'Components of Results of Operations' section of MD&A rather than 'Risk Factors', despite the section label.
- No changes were assessed beyond the text provided.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 23 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 14 sells ($743482) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 23 sells ($20M) — 5 selling insiders
- Last 180 days · read to 2026-10-040 buys · 32 sells ($29M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-05. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GKOS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding GKOS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 15,300,845
- Reported value $2,138,495,731
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about GKOS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
GKOS had 4,166,410 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
GKOS had 7.06% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.71 days to cover at the same settlement.
- Reported short interest (shares) 4,166,410
- Short interest (% of shares outstanding) 7.06%
- Prior settlement (shares) 3,821,554
- Reported change 9.02%
- Days to cover (reported) 5.71
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alcon (ALC)
- Johnson & Johnson Vision (JNJ)
- Bausch + Lomb (BLCO)
- Carl Zeiss Meditec (AFX)
- HOYA Corp (HOCPY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GKOS vs…
GLAUKOS CORP is found in…
Frequently asked questions
What does GLAUKOS CORP (GKOS) do?
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company that develops and commercializes innovative therapies for glaucoma, corneal disorders, and retinal diseases. Its portfolio includes Micro-Invasive Glaucoma Surgery (MIGS) medical devices and sustained-release pharmaceutical products. The company is transitioning its corneal cross-linking portfolio toward its newer, incision-free bio-activated therapy, Epioxa.
What sector is GLAUKOS CORP (GKOS) in?
GLAUKOS CORP (GKOS) is classified in the Health Care sector. Its industry is Ophthalmic Medical Devices & Pharmaceuticals. It trades on NYSE.
Who are GLAUKOS CORP's (GKOS) competitors?
Notable peers of GLAUKOS CORP (GKOS) include Alcon, Johnson & Johnson Vision, Bausch + Lomb, Carl Zeiss Meditec and HOYA Corp. This peer set is informational only — not financial advice.
Is GLAUKOS CORP (GKOS) overbought or oversold right now?
GLAUKOS CORP (GKOS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GKOS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.